172 related articles for article (PubMed ID: 32155756)
1. Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin.
Mariniello M; Petruzzelli R; Wanderlingh LG; La Montagna R; Carissimo A; Pane F; Amoresano A; Ilyechova EY; Galagudza MM; Catalano F; Crispino R; Puchkova LV; Medina DL; Polishchuk RS
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32155756
[TBL] [Abstract][Full Text] [Related]
2. TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.
Petruzzelli R; Mariniello M; De Cegli R; Catalano F; Guida F; Di Schiavi E; Polishchuk RS
Cells; 2022 Jan; 11(2):. PubMed ID: 35053335
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
6. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
[TBL] [Abstract][Full Text] [Related]
7. Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.
Vyas A; Duvvuri U; Kiselyov K
Biochem J; 2019 Dec; 476(24):3705-3719. PubMed ID: 31790150
[TBL] [Abstract][Full Text] [Related]
8. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(13):4578-88. PubMed ID: 15240550
[TBL] [Abstract][Full Text] [Related]
9. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.
Miyashita H; Nitta Y; Mori S; Kanzaki A; Nakayama K; Terada K; Sugiyama T; Kawamura H; Sato A; Morikawa H; Motegi K; Takebayashi Y
Oral Oncol; 2003 Feb; 39(2):157-62. PubMed ID: 12509969
[TBL] [Abstract][Full Text] [Related]
10. Role of copper transporters in platinum resistance.
Kilari D; Guancial E; Kim ES
World J Clin Oncol; 2016 Feb; 7(1):106-13. PubMed ID: 26862494
[TBL] [Abstract][Full Text] [Related]
11. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.
Nakayama K; Miyazaki K; Kanzaki A; Fukumoto M; Takebayashi Y
Oncol Rep; 2001; 8(6):1285-7. PubMed ID: 11605050
[TBL] [Abstract][Full Text] [Related]
12. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
13. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
14. Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma.
Higashimoto M; Kanzaki A; Shimakawa T; Konno S; Naritaka Y; Nitta Y; Mori S; Shirata S; Yoshida A; Terada K; Sugiyama T; Ogawa K; Takebayashi Y
Int J Mol Med; 2003 Mar; 11(3):337-41. PubMed ID: 12579336
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
16. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
17. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S
Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy.
Kuo MT; Huang YF; Chou CY; Chen HHW
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201235
[TBL] [Abstract][Full Text] [Related]
20. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
